Side effects of immune checkpoint inhibitor treatment of urological tumors

被引：6

作者：

Grimm, Marc-Oliver ^{[1
]}

Gottschlich, Tobias ^{[1
]}

Ali, Nalyan ^{[1
]}

Foller, Susan ^{[1
]}

Leucht, Katharina ^{[1
]}

机构：

[1] Univ Klinikum Jena, Urol Klin & Poliklin, Klinikum 1, D-07747 Jena, Germany

来源：

UROLOGE | 2021年 / 60卷 / 06期

关键词：

Immune-mediated adverse events; Side effects; Immune checkpoint inhibitors; Renal cell cancer; Urothelial cancer; CISPLATIN-INELIGIBLE PATIENTS; UROTHELIAL CARCINOMA; 1ST-LINE TREATMENT; SINGLE-ARM; PEMBROLIZUMAB; MONOTHERAPY; MULTICENTER; MANAGEMENT; DIAGNOSIS; SUNITINIB;

D O I：

10.1007/s00120-021-01550-4

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors (ICI) are currently routinely used for the treatment of advanced or metastatic urothelial and renal cell carcinomas. Furthermore, several clinical trials are currently investigating their role in adjuvant and neoadjuvant settings as well as in high-risk non-muscle-invasive bladder cancer. As a result, urologists are increasingly confronted with patients who are currently receiving, have recently received or will receive ICI treatment. Care is often interdisciplinary, with urologists playing a central role. Therefore, a profound understanding of immune-mediated adverse events and their differential diagnoses with respect to side effects of other medications in combination treatment are therefore extremely important. This article focusses on the prevention, early diagnosis and clinical management of the most relevant immune-related side effects derived from the new VEGFR-TKI/ICI combinations.

引用

页码：803 / 815

页数：13

共 40 条

[1] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial [J].

Albiges, Laurence ;

Tannir, Nizar M. ;

Burotto, Mauricio ;

McDermott, David ;

Plimack, Elizabeth R. ;

Barthelemy, Philippe ;

Porta, Camillo ;

Powles, Thomas ;

Donskov, Frede ;

George, Saby ;

Kollmannsberger, Christian K. ;

Gurney, Howard ;

Grimm, Marc-Oliver ;

Tomita, Yoshihiko ;

Castellano, Daniel ;

Rini, Brian, I ;

Choueiri, Toni K. ;

Saggi, Shruti Shally ;

McHenry, M. Brent ;

Motzer, Robert J. .

ESMO OPEN, 2020, 5 (06)

[2] A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors [J].

Arnaud-Coffin, Patrick ;

Maillet, Denis ;

Gan, Hui K. ;

Stelmes, Jean-Jacques ;

You, Benoit ;

Dalle, Stephane ;

Peron, Julien .

INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) :639-648

[3] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[5] Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline [J].

Bornstein, Stefan R. ;

Allolio, Bruno ;

Arlt, Wiebke ;

Barthel, Andreas ;

Don-Wauchope, Andrew ;

Hammer, Gary D. ;

Husebye, Eystein S. ;

Merke, Deborah P. ;

Murad, M. Hassan ;

Stratakis, Constantine A. ;

Torpy, David J. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (02) :364-389

[6] Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines [J].

Bossi, P. ;

Antonuzzo, A. ;

Cherny, N. I. ;

Rosengarten, O. ;

Pernot, S. ;

Trippa, F. ;

Schuler, U. ;

Snegovoy, A. ;

Jordan, K. ;

Ripamonti, C. I. .

ANNALS OF ONCOLOGY, 2018, 29 :126-142

[7] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[8]

Bristol Myers Squibb, 2021, OPD IMM MED ADV REAC

[9] Cancer immunotherapy-associated hypophysitis [J].

Castillero, Franklin ;

Castillo-Fernandez, Omar ;

Jimenez-Jimenez, Geiner ;

Fallas-Ramirez, Jose ;

Peralta-Alvarez, Marco P. ;

Arrieta, Oscar .

FUTURE ONCOLOGY, 2019, 15 (27) :3159-3169

[10]

CHMIEL K, 2011, J CLIN ONCOL, V29

← 1 2 3 4 →